Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire November 22, 2021

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

Business Wire November 5, 2021

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row  

Business Wire November 5, 2021

bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 4, 2021

bluebird bio Completes Planned Business Separation

Business Wire November 4, 2021

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

Business Wire October 18, 2021

bluebird bio Provides Update on Upcoming Planned Business Separation

Business Wire October 8, 2021

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire September 21, 2021

2seventy bio Announces Upcoming Investor Events

Business Wire September 13, 2021

bluebird bio Secures $75 Million in Private Placement Equity Financing

Business Wire September 8, 2021

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

Business Wire September 7, 2021

BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Business Wire August 13, 2021

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

Business Wire August 9, 2021

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

Business Wire August 5, 2021

bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 4, 2021

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

Business Wire July 28, 2021

BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

PR Newswire July 23, 2021

bluebird bio Receives EC Approval for SKYSONA(TM) (elivaldogene autotemcel, Lenti-D(TM)) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

Business Wire July 21, 2021

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO(TM) Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU

Business Wire July 9, 2021

BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Business Wire June 11, 2021